On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARGTM, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients 1 month and older.
On June 16, 2020, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA®, Merck & Co., Inc.) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
#CancelChildhoodCancer Advocacy Annual Summit Awareness AYA Best Practices Biorepositories CAC2 News CAC2 Project Incubator CAC2 Projects Call to Action Cancer Moonshot Clinical Trials COG Collaboration Comparative Oncology Data Delayed Diagnosis Digest Drug Development Drug Shortages Ethics Family Support FDA Funding Research Genomics Industry Perspective Member Access NCI Nutrition Patient-Reported Outcomes Prevention Psychosocial Support Rare and Ultra Rare Cancer Rare Cancers Regulations Research Research Advocacy Survivorship Venture Philanthropy
- CAC2 Childhood Cancer Community News Digest (January 30-February 5)
- CAC2 Childhood Cancer Community News Digest (January 23-29)
- CAC2 Childhood Cancer Community News Digest (January 16-22)
- CAC2 Executive Director Position Now Open!
- CAC2 Webinar–Not For Profit Financial Matters: A Deep Dive into the 990